肥胖与先天免疫标志物同银屑病生物制剂耐药相关
该横断面研究纳入87例接受生物制剂治疗至少24个月的严重斑块状银屑病患者,发现超重是早期疗效丧失而需换药的唯一临床相关因素(OR 17.3,95%CI 3.2-434.6,P=.009)。空间转录组与免疫荧光分析显示表皮先天免疫信号及中性粒细胞相关基因/蛋白表达上调,提示其可能降低生物制剂疗效持续性。
要点
- 超重(BMI>25)与生物制剂早期疗效丧失显著相关。
- 表皮先天免疫信号及中性粒细胞活性上调可能影响疗效持续性。
- 现有生物制剂主要靶向适应性免疫,靶向表皮先天免疫或为耐药新策略。
核心结论
- 表皮先天免疫反应失调和中性粒细胞活性增强可能导致生物制剂治疗反应持续性下降。
研究设计与样本
- 横断面研究,纳入2012年1月至2022年12月就诊的87例严重斑块状银屑病患者,年龄≥18岁,PASI>10且BSA>10%,既往传统治疗超过3个月且生物制剂治疗至少24个月。
主要发现
- 87例患者中16例(18.4%)因早期疗效丧失而换用其他生物制剂。
- 超重(BMI>25)是唯一临床相关因素(OR 17.3,95%CI 3.2-434.6,P=.009)。
- 空间转录组分析显示表皮中先天免疫信号及Th17/IL-17信号通路富集,TNFSF10、CXCL8、LCN2、S100A8、S100A9等基因上调。
- 配体-受体互作在IL-36家族细胞因子、抗菌肽及TNF信号中富集。
- 免疫荧光显示表皮中脂质运载蛋白2、S100A8/A9、IL-36α、IL-36γ、IL-1RA及TRAIL蛋白表达增强。
临床怎么用
- 对超重(BMI>25)的严重银屑病患者,应预期生物制剂疗效持续性可能较差并加强监测。
- 未来可考虑开发靶向表皮先天免疫反应(包括中性粒细胞)的新型治疗策略。
局限性
- 横断面设计无法确定因果关系。
- 样本量较小(87例),耐药组仅16例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Currently available biologics specifically target dermal adaptive immune molecules, such as interleukin (IL)-17 and IL-23, which are crucial in the pathogenesis of psoriasis. Despite their remarkably enhanced therapeutic effects compared with those of traditional anti-inflammatory systemic medications, 25% to 50% of patients are still resistant to biologic therapy. OBJECTIVE: To delineate the inflammatory microenvironmental factors that affect sustained treatment response in patients with severe psoriasis. DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional study was carried out including patients aged 18 years or older who visited the Gachon University Gil Medical Center dermatology clinic between January 2012 and December 2022 with plaque-type severe psoriasis with a Psoriasis Area and Severity Index score greater than 10 and body surface area larger than 10 despite conventional treatment with cyclosporine, methotrexate, acitretin, and phototherapy for longer than 3 months, and treatment with biologics for at least 24 months. Analysis was carried out from December 2023 to September 2024. MAIN OUTCOME AND MEASURE: Clinical and inflammatory factors associated with sustained response to biologics therapy. RESULTS: Among the 87 patients (mean [SD] age, 42.2 [12.5] years; 24 female patients and 63 male patients) included in the study, 16 (18.4%) had to switch to other biologics because of an early loss of therapeutic efficacy. Having overweight (body mass index, >25) was the only clinically relevant factor (odds ratio, 17.3; 95% CI, 3.2-434.6; P = .009). Other factors, including initial disease severity before biologics or disease duration until the first use of biologics, were not different between patients with treatment-resistant disease and those with a sustained treatment response. Spatial transcriptomics pathway analyses revealed enriched innate immune signaling and T-helper 17 cells (Th17)/IL-17 signaling pathways, with upregulated expression of innate immune- or neutrophil-related genes, such as TNFSF10, CXCL8, LCN2, S100A8, and S100A9, mainly in the epidermis. Enriched ligand-receptor interactions were observed in the IL-36 family of cytokines, antimicrobial peptides, and tumor necrosis factor (TNF) signaling. Immunofluorescence analysis showed enhanced protein expression of lipocalin 2, S100A8/A9, IL-36α, IL-36γ, IL-1RA, and TNF-related apoptosis-inducing ligand (TRAIL) in the epidermis. CONCLUSIONS AND RELEVANCE: This cross-sectional study found that dysregulated innate immune responses in the epidermis and heightened neutrophil activity may be responsible for decreased sustainability of therapeutic responses to biologics. Given that current biologics mainly target dermal adaptive immune-related mediators, the development of novel therapeutic strategies to target the epidermal innate immune response, including neutrophils, is warranted.
引用
- Kim HJ, Lee EH, Jung Y, et al. Association of Obesity and Innate Immune Markers With Resistance to Biologic Therapy in Psoriasis. JAMA Dermatol. 2025. PMID: 40172874. doi:10.1001/jamadermatol.2025.0288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。